Clinical trial
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Intravenous LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Had Disease Progression or Are Intolerant to Prior Therapy
NCT03886662 is registered in ClinicalTrials.gov with Lixte Biotechnology Holdings, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Study Evaluating the Safety and Efficacy of Intravenous LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Had Disease Progression or Are Intolerant to Prior Therapy
- Lead sponsor
- Lixte Biotechnology Holdings, Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- April 30, 2019
- Completion date
- July 31, 2021
- Enrollment
- 47 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.